AbolerIS Pharma

AbolerIS Pharma is a Belgian clinical-stage biopharmaceutical company founded in November 2019.

The company develops novel immunomodulatory therapies aimed at restoring immune tolerance for patients with chronic autoimmune and inflammatory diseases. It was established by three prominent scientists: Dr. Carole Guillonneau, Dr. Ignacio Anegon, and Dr. François-Xavier Hubert, who are all affiliated with the Nantes University Hospital in France. The company is currently conducting Phase 1 studies, with its lead product, ABO21009, a humanized monoclonal antibody targeting CD45RC. This therapy is designed to deplete effector T cells while preserving regulatory and memory T cells, primarily targeting conditions such as Rheumatoid Arthritis, Inflammatory Bowel Disease, and organ transplantation. AbolerIS Pharma also focuses on a secondary strategy involving IL-34 cytokine to induce tolerogenic macrophages and regulatory T cells, addressing chronic autoimmune and inflammatory conditions. The company aims to provide innovative solutions for patients with unmet medical needs in these areas.